# Ipamorelin Dosage in Research: Doses Studied, Half-Life, and Routes > Ipamorelin dosage as studied in research: the doses given to which species by which route, the ~2-hour human half-life, and handling notes — described as research context, never as a human protocol. What was administered to which species, by which route, for how long. Research context only, never a human protocol. ## Read this first This page describes ipamorelin dosage the way the studies recorded it — which doses were given to which animals or volunteers, by which route, and for how long. It is not a how-to and not a recommendation. Ipamorelin is not an approved medicine, and there is no established human dose; the numbers below are research figures, written in the third person. The one solid human pharmacokinetic fact is the half-life: about 2 hours after intravenous dosing in healthy volunteers, with a single growth-hormone pulse peaking near 40 minutes [2]. Most efficacy work is in rodents, given under the skin (subcutaneous) or into the vein (intravenous). Community protocols that pair ipamorelin with CJC-1295 by subcutaneous injection have no peer-reviewed human dosing basis at all — they are described here as anecdotal context, not as anything to follow. ## Doses studied, by species and route The published doses span a wide range because they served different experimental questions. The human PK/PD study used single intravenous infusions of 4.21–140.45 nmol/kg over 15 minutes [2]. The human Phase 2 ileus trial used 0.03 mg/kg IV twice daily for up to 7 days [3]. The rat bone-growth study used 18, 90, and 450 µg/day subcutaneously, divided three times daily [4]. The 2024 ferret cachexia study used 1–3 mg/kg intraperitoneally [5]. Routes that have been studied include intravenous (human PK and clinical trials; rodent efficacy), subcutaneous (the dominant route in rodent body-composition work and in community use), intranasal (rodent PK, roughly 20% bioavailability), and intraperitoneal (rodent and ferret efficacy). Ipamorelin itself is not orally bioavailable — only engineered ipamorelin-derived analogs achieved meaningful oral absorption, and only in animals, which the [ipamorelin oral](/oral) page covers in full. ## How much cjc-1295 ipamorelin should i take There is no answer to "how much cjc-1295 ipamorelin should i take" that comes from controlled human evidence, because the combination has never been dosed in a controlled human trial for any outcome [3]. This site does not provide a human dose for either peptide. What the literature offers is research context: ipamorelin's human work used intravenous infusions and a 0.03 mg/kg IV trial dose [2][3], and CJC-1295's single-agent human study used 30–60 µg/kg subcutaneously [10]. Subcutaneous "stack" regimens circulating in communities have no peer-reviewed human dosing basis. ## Half-life and pharmacokinetics Ipamorelin's terminal half-life in healthy human volunteers is approximately 2 hours after intravenous dosing, with clearance of 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg [2]. The growth-hormone response is a single discrete pulse peaking around 40 minutes (0.67 h) post-dose, not a sustained elevation [2]. In rats, plasma clearance is roughly five-fold lower than that of GHRP-6, indicating greater metabolic stability within the class. The short half-life and discrete-pulse pharmacodynamics are central to why GH secretagogues are studied as pulsatile rather than continuous signals. ## Handling and stability of research material Ipamorelin is supplied as a lyophilized (freeze-dried) powder — either the free base or the acetate salt — and reconstituted with bacteriostatic water for research handling. As a peptide, it is subject to degradation by heat and by repeated freeze-thaw cycles, so reconstituted solution is typically kept refrigerated. These are general peptide-handling observations drawn from the research-supply literature; they describe how research material behaves, not a clinical preparation instruction. ## How to reconstitute cjc-1295 ipamorelin 5mg Questions like "how to reconstitute cjc-1295 ipamorelin 5mg" come up because these peptides ship as lyophilized powder that must be dissolved before use. As general research-handling context: lyophilized peptide is reconstituted with bacteriostatic water, kept refrigerated, and protected from heat and repeated freeze-thaw to limit degradation. This site does not provide a preparation protocol for human use — ipamorelin is not an approved medicine and no human dosing pathway is described here. The note is provenance for how research-grade material is handled, nothing more. --- A forward-looking reading of the ipamorelin record — the clean cortisol-sparing GH pulse celebrated for the design feat it is, the single failed human trial and the 2024 FDA tightening kept in plain view, and the community reports pinned to one side as anecdote; no clinic behind the page and nothing here dosed, compounded, prescribed, or sold.